Industry Science Updates

Keytruda – what a 40% response rate has meant to me.

By Bill Drake, TargetCancer Foundation Advocacy Council Member

On September 11, 2013 I was diagnosed with an adenocarcinoma malignant tumor on my esophagus at my GI junction, inside my GI specialist’s office on Cape Cod. I was there for my routine “over 50” colonoscopy. Continue reading

Washington DC Recap: ACA Repeal and Its Impact on Cancer Patients

By TargetCancer Foundation Advocacy Council Member DJ Webster

Last Thursday, TargetCancer Foundation traveled to Washington D.C. for the annual in-person meeting of the Deadliest Cancers Coalition, a collaboration of national non-profit organizations that TargetCancer is a member of. The DCC is focused on addressing policy issues related to our nation’s deadliest (or recalcitrant) cancers, defined as those that have five-year survival rates below 50 percent, which includes both esophageal cancer and cholangiocarcinoma. Continue reading

United against rare diseases.

Did you know that in the US, a disease is considered rare if it affects under 200,000 people? “Rare” doesn’t mean much, however,  if you or someone you love is diagnosed a rare disease- you just want to know what to do, which doctor to see, and how to find the best treatment.

Continue reading

Our inaugural post.

Welcome to the TargetCancer Foundation Blog! We are thrilled to introduce this new platform for all things related to TargetCancer Foundation.

Continue reading